Rigel Pharmaceuticals reported $16.61M in Gross Profit on Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Agenus AGEN:US USD 22.46M 3.56M
Amgen AMGN:US USD 5.06B 20M
AstraZeneca AZN:LN USD 8.86B 3M
Astrazeneca AZN:US USD 8.86B 3M
Biomarin Pharmaceutical BMRN:US USD 389.06M 21.62M
Bristol Myers Squibb BMY:US USD 8.86B 345M
Daiichi Sankyo 4568:JP JPY 242.71B 37.19B
Eli Lilly And LLY:US USD 5.36B 305M
Halozyme Therapeutics HALO:US USD 161.66M 43.24M
Intrexon XON:US USD 15.14M 14.04M
Karyopharm Therapeutics KPTI:US USD 35.16M 3.58M
MacroGenics MGNX:US USD 38.59M 14.99M
Neurocrine Biosciences NBIX:US USD 381.8M 8.4M
Pfizer PFE:US USD 16.55B 2.52B
Regeneron Pharmaceuticals REGN:US USD 2.62B 58.3M
Ultragenyx Pharmaceutical RARE:US USD 82.07M 999K
Veracyte VCYT:US USD 49.58M 1.75M